STEP 8 directly compared two injection regimens in 338 adults without diabetes [1]. When reading about weight loss across GLP-1 trials, check which drug, dose and follow-up each study used.
Weight loss at 68 weeks
Mean weight change was −15.8% with weekly semaglutide 2.4 mg and −6.4% with daily liraglutide 3.0 mg [1]. The difference was −9.4 percentage points (95% CI −12.0 to −6.8). All groups received counseling on diet and physical activity.
At least 10% weight loss was reached by 70.9% on semaglutide and 25.6% on liraglutide. The active comparison was open-label, so participants knew which of the two drugs they received.
Digestive effects and stopping treatment
Digestive adverse events affected 84.1% on semaglutide and 82.7% on liraglutide [1]. Adverse events led to stopping treatment for 3.2% and 12.6%, respectively. The figures for stopping for any reason were 13.5% and 27.6%, respectively.
Studies of why people stop GLP-1 treatment outside trials include factors such as cost and access. STEP 8 compared tolerability under trial conditions.
What a Greek payer model adds
A 68-week Greek model estimated that semaglutide cost the payer more per course [2]. It estimated a lower cost per patient reaching 5% weight loss: €3,768.72 with semaglutide and €4,718.66 with liraglutide. These figures depend on local prices and the chosen weight-loss threshold.